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Through its binding with protein S (PS), a
key element of the coagulation/fibrinoly-
sis cascade, the C4b-binding protein
(C4BP) has been hypothesized to be in-
volved in the susceptibility to venous
thrombosis (VT). To identify genetic fac-
tors that may influence the plasma levels
of the 3 C4BP existing isoforms, 71,
61, and 70, we conducted a genome-
wide association study by analyzing
283 437 single nucleotide polymorphisms
(SNPs) in the Genetic Analysis of Idio-
pathic Thrombophilia (GAIT) study com-
posed of 352 persons. Three SNPs at the
C4BPB/C4BPA locus were found genome-
wide significantly associated with 70
levels. One of these SNPs was further
found to explain approximately 11% of
the variability of mRNA C4BPA expres-
sion in the Gutenberg Heart Study com-
posed of 1490 persons, with no effect on
C4BPB mRNA expression. The allele asso-
ciated with increased 70 plasma levels
and increased C4BPA expression was
further found associated with increased
risk of VT (odds ratio [OR]  1.24 [1.03-
1.53]) in 2 independent case-control stud-
ies (MARseille THrombosis Association
study [MARTHA] and FActeurs de RIsque
et de re´cidives de la maladie thromboem-
bolique VEineuse [FARIVE]) gathering
1706 cases and 1379 controls. This SNP
was not associated with free PS or total
PS. In conclusion, we observed strong
evidence that the C4BPB/C4BPA locus is
a new susceptibility locus for VT through
a PS-independent mechanism that re-
mains to be elucidated. (Blood. 2010;
115(23):4644-4650)
Introduction
Protein S (PS), a vitamin K–dependent plasma protein, is a key
regulator of the coagulation/fibrinolysis cascade. PS has no enzy-
matic activity but acts mainly as a cofactor for activated protein C
(APC).1 It participates in the inactivation of factors Va (FVa) and
FVIIIa, leading to inhibition of thrombin generation.2-4 Even in
absence of APC, PS could still inhibit thrombin generation by
decreasing the conversion of prothrombin to thrombin and that of
FX to FXa.5 PS is also a cofactor for tissue factor pathway inhibitor
(TFPI) for inhibiting FXa.6
In plasma, PS circulates either in a free form (fPS; 40%) or as
a complex with the C4b-binding protein (C4BP; 60%).7-10 It was
initially thought that the C4BP-bound PS was not active and that
only the circulating fPS was.7-9 However, more recent works shed
new light on a more complex mechanism, as C4BP-PS complex
was shown to directly participate in the FVa and FVIIIa inactiva-
tion,11 and C4BP could inhibit APC-catalyzed FVa inactivation
even in the absence of PS.12 Such complex and elusive mechanisms
could explain why, despite the key role of PS in the regulation of
thrombin generation, its involvement in the susceptibility of
venous thrombosis (VT) remains obscure. Although PS deficiency
is considered a risk factor for VT,13-15 total PS and fPS show very
little correlation with VT.16,17
C4BP is a large plasma protein existing in 3 different isoforms,
71, 70, and 61, according to the number of identical -chains
(6 or 7) and the presence/absence of a single -chain.18 The main
isoform is 71, whereas the 70 isoform lacking the -chain
represents approximately 17% of the C4BP molecules.7,18 Whereas
the -chain binds for many ligands,19 the -chain is specific for the
binding of PS. As a consequence, the amount of -chain–
containing isoforms can be viewed as a surrogate marker for fPS
levels. Plasma levels of all 3 isoforms have documented high
heritability estimates ( 40% each),20 but little is know about their
genetic determinants other that they seem to segregate with the
C4BPA and C4BPB genes in 1q32.21
The objective of this work was to search for single nucleotide
polymorphisms (SNPs) that could influence plasma levels of C4BP
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isoforms and to investigate whether such SNPs could influence the
risk of VT. Our working hypothesis was that SNP(s) associated
with both plasma levels of some specific C4BP isoform(s) and VT
risk would provide new insights into the mechanisms relating PS
(either fPS, total PS, or both) to VT susceptibility. For this purpose,
a genome-wide association study (GWAS) of plasma levels of
C4BP isoforms was first performed in Spanish pedigrees from the
Genetic Analysis of Idiopathic Thrombophilia (GAIT) study22 in
parallel with a SNP-expression association analysis of mRNA
levels of the C4BPA and C4BPB genes coding for the - and
-chains, respectively, in the Gutenberg Heart Study.23 These
analyses were followed up in 3 independent samples with an in
silico GWAS and 2 case-control candidate gene studies for VT.24
Methods
Subjects
All studies were approved by the institutional ethics committees of all
participating institutions and their extensive descriptions have been pro-
vided elsewhere: in Souto et al22 for the GAIT study; in Tre´goue¨t et al24 for
the GWAS, MARseille THrombosis Association study (MARTHA), and
FActeurs de RIsque et de re´cidives de la maladie thromboembolique
VEineuse (FARIVE) studies; and in Zeller et al23 for the Gutenberg Heart
Study. A brief description of these studies follows.
GAIT study. The GAIT study is composed of 21 extended Spanish
pedigrees including 352 persons. Twelve families were ascertained though a
proband with idiopathic thrombophilia, whereas 9 families were randomly
selected. Thrombophilia was defined either as multiple thrombotic events, a
single spontaneous episode with at least 1 affected first-degree relative, or
an early age of onset ( 45 years). Idiopathic status of a person was defined
as absence of known risk factors such as antithrombin, protein C or
protein S deficiencies, activated PC resistance, factor V Leiden, and lupus
anticoagulant. In the entire sample, 33 persons had venous thrombosis.
Participant age ranged from 1 to 87 years, with a median of 38 years.
Gutenberg Heart Study. This report was based on the analysis of 1490
unrelated healthy controls of German origin who participated in the
community-based Gutenberg Heart Study (GHS) conducted in the Rhein-
Mainz region in western mid-Germany. All subjects were aged between
35 and 74 years. Participants ascertained from the registers of the local
registry offices were invited for a 5-hour baseline examination where
clinical examinations and collection of blood samples were performed.
DNA and mRNA were collected for all persons.
In silico GWAS data. For this part, we used data that were already
available (in silico) from our previous GWAS on VT.24 Briefly, 419 VT
cases were compared with 1228 healthy controls, all expected to be of
European origin. Cases were patients with documented early age of onset
( 50 years) objectively diagnosed VT—including deep vein thrombosis
(DVT) and/or pulmonary embolism (PE)—recruited from 4 different
French medical centers (Grenoble, Marseille, Montpellier, and Paris)
between 1999 and 2006. Exclusion criteria were acquired risk factors and
known genetic risk factors, that is, antithrombin, protein C, or protein S
deficiencies, and homozygosity for factor V Leiden or FII 20210A.
Controls were French persons selected from the Suvimax study.25
MARTHA study. The MARTHA study is a case-control study
including 1150 cases and 801 controls. Cases were unrelated whites
consecutively recruited from the Thrombophilia center of La Timone
hospital between January 1994 and October 2005. Cases were patients
without known genetic risk factor (In silico GWAS data) and lupus
anticoagulant. Thrombotic events including DVT and PE were documented
by venography, Doppler ultrasound, spiral computed tomographic scanning
angiography, and/or ventilation/perfusion lung scan. Controls were healthy
French persons without a personal history of cardiovascular disease
(including VT) selected from the Marseille area and from the national
health examination centers of French Social Security in collaboration with
the Hemostasis and Thrombosis Study Group.
FARIVE study. The FARIVE study is a multicenter case-control study
involving consecutive subjects treated as inpatients or outpatients for a first
episode of proximal DVT and/or PE. Six hundred seven VT cases were
compared with 607 healthy persons. Diagnosis for DVT was made through
venography and compression-ultrasonography, and for PE through spiral
computed tomography, high-probability ventilation/perfusion lung scan,
pulmonary angiography, and compatible physical findings in a patient with
proven DVT. Patients younger than 18 years, having already had VT, a
diagnosis of active cancer, or a history of malignancy fewer than 5 years
previously, or having a short life expectancy because of other causes were
excluded. The control group consisted of age- and sex-matched persons and
had to be free of personal and family history of venous and arterial
thrombotic disease, and free of cancer and liver or kidney failure.
C4BP measurements
A detailed description of C4BP measurements has previously been re-
ported.20 Briefly, plasma levels of C4BP and C4BP were obtained using
mouse anti–human antibodies. The percentage of C4BP -chain lacking
isoform, %70, was estimated from the ratio (C4BP  C4BP)/C4BP.
It can be viewed as the molar excess of C4BP-chain. In addition to C4BP
measurements, fPS are total PS levels were also measured through the use
of enzyme-linked immunosorbent assays from Diagnostica Stago.22
Genotyping
Pedigrees members of the GAIT study were typed with the Illumina
Infinium 317 Beadchip as previously described.26 Single nucleotide poly-
morphisms (SNPs) with a call rate less than 0.95, a minor allele frequency
less than 0.025 or deviating from Hardy-Weinberg equilibrium (HWE) at
P less than 5  107 were excluded, resulting into 283 437 SNPs left for
analysis.
GHS participants were typed with the Affymetrix Genome-Wide
Human SNP Array 6.0 as previously described.23 SNPs with a call rate less
than 0.98, a minor allele frequency less than 0.01, or deviating from
Hardy-Weinberg equilibrium at P less than 104 were excluded from the
analysis.
Persons for the initial GWAS analysis on VT were typed with the
Illumina Sentrix HumanHap300 Beadchip with genotyping quality control
criteria previously described.24 In MARTHA and FARIVE, rs3813948
genotyping was performed using TaqMan technology (Applied Biosys-
tems) with genotype success rate of 98.7% and 99.9%, respectively.
The location of all C4BPB/C4BPA SNPs studied in this report is shown
in Figure 1.
mRNA expression analysis
Detailed description of monocyte isolation and RNA extraction and
preparation can be found in Zeller et al.23 Monocytes RNA profiles were
generated using Illumina Human HT-12 expression V3 BeadChips. The
preprocessing of the expression data and the application of several filters
resulted in the identification of 12 808 genes expressed in monocytes.23
Among the genes were C4BPB, C4BPA, and PROS1 (the gene encoding for
protein S).
Statistical analysis
In all studies, deviation from Hardy-Weinberg equilibrium (HWE) was
investigated using a standard 2 with 1 degree of freedom. In the GAIT
study, HWE was tested using parental data only.
In the GAIT study, association between SNPs and C4BP-related
phenotype levels was tested using a measured genotype association analysis
assuming additive allele effects. This analysis was carried out using the
variance-components methodology implemented in the SOLAR Version
4.0 software (Southwest Foundation for Biomedical Research, http://
solar.sfbrgenetics.org/download.html).27 Analyses were adjusted for age,
sex, and smoking, and in females, for oral contraception as well. Any SNP
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was considered significantly associated with a C4BP phenotype when its
corresponding P value was less than 1.8  107; this threshold corresponds
to a family-wise error rate of .05 after applying the Bonferroni correction
for the number of tested SNPs.
In GHS, association between SNPs and mRNA expression levels was
tested by 1-way analysis of variance with 2 degrees of freedom. Single
locus association analyses of SNPs with mRNA expression were followed
by haplotype analyses to handle linkage disequilibrium (LD) between
SNPs. For this purpose, THESIAS software (Inserm UMR_S 937, http://
genecanvas.ecgene.net/downloads.php?cat_id1) was used.28 Haploview
software (Broad Institute of MIT and Harvard, http://www.broadinstitute.org/
haploview/haploview)29 was used to quantify and display the extent of
linkage disequilibrium (LD) between studied SNPs.
In the GWAS and the 2 independent case-control studies for VT, the
Cochran-Armitage trend test30 was used to test for the association of studied
SNPs with VT. When appropriate, the homogeneity of the genetic effects
across MARTHA and FARIVE, and according to subgroups defined by
categoric variables such sex, FV Leiden, FII 20210 mutations, and ABO
blood group, was tested using the Mantel-Haenszel method.31
Results
Family-based genome-wide association analysis of C4BP
phenotypes
Results of the genome-wide association analyses are summarized
in Figure 2. No SNP was found associated with plasma C4BP or
C4BP at a genome-wide significance level (Figure 2A and B,
respectively). However, analysis of %70 revealed 3 SNPs
achieving the a priori genome-wide significance threshold of
1.8  107 (Figure 2C). These SNPs were all located on chromo-
some 1q32.2 in the C4BPB/C4BPA gene cluster. One of them,
rs3813948, is located within the C4BPB gene, whereas the others,
rs11120218 and rs2808470, are located in the C4BPA (Table 1), all
intronic SNPs. For each of these 3 SNPs, the minor allele was
significantly associated with increased levels of %70. In addi-
tion, the minor allele of each of the 2 C4BPA SNPs showed
association with increased C4BP levels (P  103) but did not
reach genome-wide statistical significance (Table 1). In contrast,
these SNPs were not associated with fPS or with total PS levels
(Table 1).
Association of C4BPB/C4BPA locus with mRNA expression in
monocytes
Nineteen SNPs spanning the C4BPB/C4BPA locus were genotyped
in GHS (supplemental Table 1, available on the Blood Web site; see
the Supplemental Materials link at the top of the online article), and
all of them were in HWE. Four SNPs were strongly associated
(P  1011) with C4BPA expression, but little association was
observed with C4BPB expression (supplemental Table 1). The SNP
most strongly associated with C4BPA monocyte expression was the
C4BPA rs11120211 (R2  10.7%, P  6.7  1036), the
rs11120211-A allele being associated with higher levels in a fairly
additive model (Figure 3). Among the 3 other SNPs that were
associated with C4BPA expression, rs11120218 (P  3.53  1017)
was also associated with plasma levels of %70 and C4BP in the
GAIT study (Table 1). LD and in-depth haplotype analyses
revealed that the effect of these 3 other SNPs was due to their LD
with rs11120211, and that no other effect on C4BPA mRNA
expression levels was observed at the C4BPB/C4BPA locus beyond
that of the rs11120211 (supplemental Tables 1-2). It is worth
pointing out that C4BPB and C4BPA mRNA expressions were not
correlated (r  0.00, P  .98) and that none of the 19 genotyped
SNPs was associated with C4BPB mRNA expression, either
through single locus (supplemental Table 1) or haplotype (supple-
mental Table 2) analyses. Similarly, no association was observed
between C4BPB/C4BPA SNPs and PROS1 mRNA expression
levels (supplemental Tables 1-2), and PROS1 mRNA expression
was not correlated with C4BPA mRNA levels either (r  0.03,
P  .29).
Interestingly, looking at the HapMap II database33 revealed that
the rs11120211 located in the C4BPA proximal promoter was in
complete association with the rs3813948 identified in the GAIT
study but was not available in the DNA array used for genotyping
GHS participants. In this database, the rs11120211-A allele associ-
ated with increased C4BPA mRNA levels in GHS corresponds to
the rs3813948-C allele associated with increased plasma levels of
C4BP and %70 in the GAIT study.
In silico GWAS analysis of VT at the C4BPB/C4BPA locus
Because of the hypothesized link between C4BP isoforms and VT
risk, we investigated whether SNPs at the C4BPB/C4BPA locus
were associated with VT using an in silico association analysis of
previously published GWAS data for VT.24 Ten SNPs available in
the DNA chip array used in this GWAS were located on the
chromosome 1 region spanning the 205 320 000- to 205 400 000-
bp region harboring the C4BP/C4BPA gene cluster (supplemental
Table 3). Among these 10 SNPs, the 3 SNPs that were associated
with %70 in the GAIT study, that is, rs3813948, rs11120218, and
rs2808470, showed association with VT at P less than .05
(supplemental Table 3).
C4BPB C4BPA
rs8942
rs11120211
rs4403634 rs11120218
rs2808470
rs17020993
rs4844573
rs11120277
rs2353545
rs3813948
rs9943077
rs4348726
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rs6688299
rs11120302
GAIT
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In silico GWAS
rs6690037
rs6673422
rs4142863
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X X
X X X
X X X
rs4571969
rs2491393
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X
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Study
Figure 1. Location of the studied C4BPB/
C4BPA polymorphisms. Exons are denoted as
squares. X represents polymorphisms that were
genotyped in a given study. Underlined X de-
notes polymorphisms showing association with
any of the studied phenotypes.
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Interestingly, the SNP that was most strongly associated with
VT was the rs3813948, its minor C allele being more frequent in
VT cases than in controls (0.093 vs 0.067). This allele was the most
strongly associated with increased %70 levels in the GAIT study
(see “Family-based genome-wide association analysis of C4BP
phenotypes”) and in complete association with the rs11120211-A
allele associated with increased C4BPA expression in GHS. Be-
cause LD analysis revealed that the effect of the rs11120218 and
rs2808470 on VT risk was due to their LD with the rs3813948
(D	  
0.99, r2  0.423, and D	  
0.99, r2  0.31, respec-
tively), the influence of the rs3813948 on VT risk was further
investigated for replication in 2 independent case-control studies.
Case-control association analysis of rs3813948 with VT risk
We then genotyped the rs3813948 in 2 case-control studies for VT,
MARTHA and FARIVE. Genotype distribution of the rs3813948
followed HWE law in both studies (Table 2). In both studies, the
rs3813948-C allele tended to be slightly more frequent in cases
than in controls (0.091 vs 0.079), without reaching the significance
level of .05 in any of the 2 studies. However, marginal significance
association (P  .046) was obtained when the results of the
2 studies were combined. In the pooled samples, the rs3813948-C
allele was associated with a slight increased risk of VT (OR 1.239
[1.003-1.530]; P  .046). This effect of rs3813948 on VT risk did
not show heterogeneity with respect to sex, ABO blood group, and
FV and FII Leiden mutations (data not shown). It is noteworthy that
the combined sample of 1706 cases and 1379 controls provided
limited power (ie, 56%) to detect such genetic effect at a .05
significance level.
Discussion
Using a multistep strategy relying on different study designs, we
were able to show that the C4BPB/C4BPA gene cluster is a new
susceptibility loci for VT, likely through an effect on C4BPA
mRNA expression.
The starting point of this work was to search for SNPs
associated with both plasma levels of specific(s) C4BP isoform(s)
and VT risk, with the aim of getting a better understanding of the
mechanisms relating PS to VT susceptibility. We were successful at
finding 1 SNP influencing plasma levels of the percentage of 70
relative to the amount of C4BP-chain, which was also associated
with VT risk, but independently of PS as initially hypothesized.
Figure 2. Manhattan plots obtained from the genome-wide association analyses of the plasma levels of C4BP (A), C4BP (B), and %70 (C) performed in the GAIT study.
The solid horizontal line indicates the genome-wide statistical significance level of 1.8  107.
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Indeed, in the GAIT study, this SNP did not show any evidence for
association with fPS or total PS, despite its location within the
previously identified linkage peak for free PS.34 These results
suggest a pleiotropic effect of the locus on different phenotypes
related to C4BP.16 To sum up, the effect of this SNP was observed
on C4BPA mRNA expression, plasma levels of %70, to a lesser
extent on those of total C4BP, and on VT risk but not on fPS or
total PS.
These observations suggest that molecular excess of C4BP-chains
unbound to C4BP-chain could be a new disease-associated mecha-
nism relating C4BPB/C4BPA locus to VT susceptibility independently
of PS regulation. This hypothesis is supported by several studies
showing that increased plasma levels of C4BP-chains, but not of
C4BP-chains, are observed during inflammation,35,36 a biologic pro-
cess whose role in thrombosis is increasingly advocated.37-40 Interest-
ingly, the C4BP-chain has binding sites for many ligands such as
CD40, CRP, and heparin,41,42 which are key molecules involved in
inflammatory and coagulation pathways.38,39 The hypothesis raised by
our work suggesting the implication of C4BP independently of PS
regulation is further supported by the observation that C4BP participates
in FVa inactivation even in the absence of PS.12
Several SNPs spanning the C4BPB/C4BPA locus were studied
in this report and, because some of them were in complete
association with each other, it is not possible from the current report
to draw any definitive conclusions about the functional variant
responsible for the observed associations. This could be the
rs3813948 lying in the C4BPB gene intron 4, the rs11120211 in the
C4BPA proximal promoter, or any other SNP in complete associa-
tion with them. According to HapMap database, additional candi-
dates could be the rs17020634 and rs12063780 located in C4BPA
proximal promoter or the C4BPA intronic rs12057769 and
rs17020983. Because SNPs of interest explained up to 11% of
C4BPA mRNA expression with no effect of C4BPB mRNA, it is
more likely that the C4BPA promoter harbors the culprit. This
hypothesis should further be investigated using in vitro functional
studies. It could be argued that investigating C4BP mRNA
expressions in monocytes, as we did here, is not relevant in the
context of VT. However, the increasingly recognized role of C4BP
in inflammation,36,41,43,44 where monocytes are major players,
justifies our rationale of using this type of cell for determining
SNPs associated with C4BPB/C4BPA mRNA expressions.
Table 1. Association* of the C4BPB/C4BPA SNPs identified through the GAIT GWAS with plasma levels of C4BP, C4BP, 70, free PS,
and total PS
Gene/rsID (position, bp)/
genotype
Phenotype
C4BP C4BP %70 fPS Total PS
C4BPB
rs3813948 (205 336 481)
TT (n  313) 323.1 (79.37) 256.4 (51.94) 19.3 (10.24) 97.0 (21.27) 102.2 (19.73)
TC (n  37) 335.5 (80.67) 231.1 (42.06) 30.0 (7.35) 92.7 (19.25) 94.5 (19.12)
CC (n  2) 354.8 (63.92) 238.0 (58.69) 33.3 (4.53) 97.0 (16.97) 93.5 (16.26)
R2, % 0.87 1.56 10.98 0.01 0.71
P .0687 .0326 4.37  1010 .9321 .1842
C4BPA
rs11120218 (205 345 074)
GG (n  235) 315.1 (77.42) 252.9 (52.01) 18.5 (10.41) 97.5 (21.35) 101.4 (19.35)
GA (n  112) 341.9 (77.95) 255.6 (50.34) 24.2 (9.34) 94.7 (22.44) 101.4 (20.78)
AA (n  5) 383.8 (124.03) 244.7 (62.06) 35.3 (5.76) 93.0 (19.45) 97.4 (19.50)
R2, % 3.81 0.01 10.62 0.41 0.00
P 5.64  104 .8979 1.55  109 .1999 .5523
rs2808470 (205 353 810)
CC (n  221) 315.8 (77.21) 254.0 (52.17) 18.3 (10.64) 97.0 (20.91) 102.1 (18.95)
CT (n  122) 338.6 (79.96) 253.8 (50.71) 23.9 (8.99) 95.9 (21.55) 101.9 (21.25)
TT (n  9) 345.2 (108.26) 234.6 (52.41) 30.2 (10.96) 97.3 (20.34) 101.4 (21.15)
R2, % 2.77 0.01 9.80 0.12 0.02
P 1.35  103 .9615 3.36  109 .4676 .6502
R2 represents the percentage of variance explained by the genotype.
GAIT indicates Genetic Analysis of Idiopathic Thrombophilia; fPS, free Protein S; GWAS, genome-wide association study; and PS, Protein S.
*Mean (SD).
Table 2. Genotype distribution of the C4BPB rs3813948 according to VT status in the MARTHA and FARIVE case-control studies
rs3813948
MARTHA FARIVE MARTHA and FARIVE
Controls, n  789 (%) Cases, n  1110 (%) Controls, n  590 (%) Cases, n  596 (%) Controls, n  1379 (%) Cases, n  1706 (%)
TT 672 (85) 922 (83) 501 (85) 491 (82) 1173 (85) 1413 (83)
TC 110 (14) 175 (16) 85 (14) 101 (17) 195 (14) 276 (16)
CC 7 (1) 13 (1) 4 (1) 4 (1) 11 (1) 17 (1)
MAF 0.079 0.091 0.079 0.091 0.079 0.091
OR* 1.171 (0.911-1.506); P  .217 1.204 (0.884-1.639); P  .238 1.181 (0.972-1.434); P  .093
OR† 1.239 (0.936-1.639); P  .134 1.239 (0.900-1.705); P  .189 1.239 (1.003-1.530); P  .046
MARTHA indicates MARseille THrombosis Association study; FARIVE, FActeurs de RIsque et de re´cidives de la maladie thromboembolique VEineuse; MAF, minor allele
frequency; and OR, odds ratio.
*Crude odds ratio for VT associated with carrying the C allele (dominant model).
†OR adjusted for age, sex, FV and FII mutations, and ABO blood group.
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Despite the rather strong association of the identified SNP with
both C4BPA mRNA expression and plasma levels of 70, this SNP
explaining approximately 11% of their variability, it was associated
with only a modest increased risk of VT (OR  1.24). This effect
was not identified from our previous GWAS on VT24 due to mainly
lack of power related to the use of stringent statistical threshold and
moderate sample sizes. This highlights some limitations of the
current GWAS approach and the need for gathering well-powered
and carefully designed epidemiologic studies, and using alternative
and complementary research strategies, as we did here, to identify
the factors underlying genetic susceptibility to VT.45
The main limitation of this work is that neither 70 plasma
levels nor C4BPA mRNA expression was available in our VT
case-control samples. Without such information, it is not possible
to definitively claim that the observed association between C4BPB/
C4BPA locus and VT risk is mediated through an effect on CBPA
mRNA, and then through an excess 70 isoform. However, the
concomitant association of the same allele with both increased
levels of C4BPA and 70 and VT risk strongly favors this
hypothesis.
In conclusion, this work provides strong evidence that the
C4BPB/C4BPA locus is a new susceptibility locus for VT, whose
functional variant(s) remains to be identified. In addition, the
biologic mechanisms linking this locus to VT appears independent
of the protein S regulation, opening a new research area focusing
on C4BP regulatory pathway.
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